Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors.
about
Kinase signaling and targeted therapy for primary myelofibrosis.The CNS penetrating taxane TPI 287 and the AURKA inhibitor alisertib induce synergistic apoptosis in glioblastoma cells.Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.
P2860
Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Open-label, multicenter, phase ...... in patients with solid tumors.
@en
type
label
Open-label, multicenter, phase ...... in patients with solid tumors.
@en
prefLabel
Open-label, multicenter, phase ...... in patients with solid tumors.
@en
P2093
P2860
P356
P1433
P1476
Open-label, multicenter, phase ...... in patients with solid tumors.
@en
P2093
Celestia S Higano
E Jane Leonard
John Sarantopoulos
Julie N Graff
Karthik Venkatakrishnan
Matthew H Taylor
Noah M Hahn
Xiaofei Zhou
P2860
P304
P356
10.1002/CNCR.30073
P407
P577
2016-05-18T00:00:00Z